BSH 2023 | Results from AGILE: ivosidenib-azacitidine vs azacitidine-placebo in patients with IDH1m AML
Vidhya Murthy, MBBS, MRCP, FRCPath, FRCP, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses results from the Phase III AGILE trial (NCT03173248), which investigated the safety and efficacy of ivosidenib-azacitidine versus azacitidine-placebo in older patients with IDH1-mutated acute myeloid leukemia (AML) unfit for intensive chemotherapy. Results demonstrated that patients in the ivosidenib-azacitidine arm demonstrated a superior event-free survival (EFS) and overall survival (OS), as well as an improved neutrophil count. Dr Murthy also discusses quality of life (QoL) data obtained in this trial and the toxicity profile of this combination. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
